James Michael Dunn
Physician at Hinsdale Pl, Littleton, CO

6447807, Sep 10, 2002

Sep 14, 2000

09/661665

Dallas L. Clouatre - Menlo Park CA 94025
James M. Dunn - Littleton CO 80112

A61K 916

424494, 424400, 424439, 424441, 424468, 424499

A method for making the potassium and sodium salts of (-)-hydroxycitric acid and mixtures thereof workable, non-hygroscopic and non-reactive in acidic media by encasement in hydrophobic and acidophobic polymers. The calcium and magnesium salts of (-)-hydroxycitric acid likewise can be rendered nonreactive in acidic media. The resulting products are suitable for tableting, encapsulation and use in other dry media for weight loss, appetite suppression, improvements in fat metabolism and postprandial lipemia and other pharmaceutical purposes. Further, the products of this invention can be made nonreactive as components of acidic liquid drink mixes and snack bars and can be used in the production of controlled release administration formats.

6441041, Aug 27, 2002

Jun 20, 2001

09/886499

Dallas L. Clouatre - Palo Alto CA 94301-1704
James M. Dunn - Littleton CO 80112

A61K 3119

514574

(-)-Hydroxycitrate (HCA) supplementation constitutes a novel means of reducing the loss in bone mineral content such as that usually found in osteoporosis and the related loss in bone quality (protection against the corticoid-induced loss in non-mineral bone components). Similarly, HCA supplementation constitutes a novel means of reducing stress-induced bone loss and of reducing other forms of bone loss induced by glucocorticoid-related mechanisms. The discovery that HCA has bone loss-moderating effects allows for the creation of novel and more efficacious approaches to preventing osteoporosis and for maintaining normal bone metabolic functioning even in the face of diet and exercise habits which are less than ideal and in the face of chronic stress. Furthermore, this discovery makes possible the development of adjuvant modalities which can be used to improve the results realized through the employment of conventional anti-osteoporosis/bone protective remedies. Controlled release can be used to provide a sustained and modulated amount of the active to the body as desired and therefore to regulate the use of the compound.

6482858, Nov 19, 2002

Jun 20, 2001

09/886572

Dallas L Clouatre - Palo Alto CA 94301-1704
James M Dunn - Littleton CO 80112

A61K 31194

514574

HCA Supplementation improves wound healing and immunomodulation/immunoregulation, including improving depressed immune function and also reducing excessive immune activity such as is found in elevated humoral immunity linked to allergies and autoimmune diseases. The benefits of HCA are especially pronounced with the use of the preferred salt of the acid, potassium hydroxycitrate, and may be further potentiated by the use of a controlled-release form of the compound.

6207714, Mar 27, 2001

Sep 14, 2000

9/661588

Dallas L. Clouatre - Palo Alto CA
James M. Dunn - Littleton CO

A61K31/19

514574

A method whereby the glucose metabolism in an individual showing evidence of dysregulation, as is found in insulin resistance, reactive hyperglycemia and/or elevated blood sugar levels and/or diabetes, is improved when that person receives an appropriate oral administration of (-)-hydroxycitric acid. The potassium salt of (-)-hydroxycitric acid is the preferred form of the compound, followed by the sodium salt. The regulation of glucose levels over any given period of time may be improved with a controlled release form of (-)-hydroxycitric acid. Controlled release can be used to provide a sustained and modulated amount of the active to the body as desired and therefore regulate the use of the compound as a hypoglycemic agent.

2006029, Dec 28, 2006

Mar 8, 2006

11/371270

Dallas Clouatre - Santa Monica CA, US
James Dunn - Littleton CO, US
Caroline Dunn - Littleton CO, US

A61K 31/19, A61K 9/64, A61K 9/24

424456000, 424472000, 514574000

The present invention provides stable encapsulated (−)-hydroxycitric acid (“HCA”) dosage unit forms, uses thereof, as well as and methods of making the same. In particular, HCA and the salts, esters and amides of HCA according to the invention are delivered via enteric vehicles, such as enteric-coated tablets, and also enteric and enteric-coated capsules and soft gelatin capsules (softgels). Enteric-coatings may be applied externally to the HCA-containing dosage unit form or, in the case of capsules and soft gelatin capsules, the enteric compound also may be incorporated into the gelatin shell to yield an HCA-containing dosage unit form of the invention. The HCA-containing compositions are protected against acid degradation, lactonization and undesirable ligand binding in select environments. The invention provides HCA-containing dosage unit forms useful to prevent or reduce the symptoms associated with a disease, disorder or condition such as obesity, weight gain, hunger, hyperlipemia, and postprandial lipemia.

2006014, Jun 29, 2006

Nov 28, 2005

11/287905

Dallas Clouatre - Santa Monica CA, US
James Dunn - Littleton CO, US
Caroline Dunn - Littleton CO, US

A61K 9/20, A61K 31/19

424464000, 514574000

The present invention provides stable encapsulated (−)-hydroxycitric acid (“HCA”)-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable (that is, not prone to lactonization, not readily subject to attachment to ligands which inhibit absorption or lead to excretion, and so forth) such that these HCA salts might be included in dry delivery formats, liquid delivery and in controlled-release vehicles. The nonhygroscopic salts of HCA and its derivatives likewise may be protected against acid degradation, lactonization and undesirable ligand binding when exposed to acidic environments or other challenging conditions. The method taught herein can be employed to reduce the polar/ionic qualities of HCA salts and derivatives when presented to the intestinal lumen to provide advantages in absorption.

4521402, Jun 4, 1985

Feb 17, 1984

6/581368

James M. Dunn - Littleton CO

Verex Laboratories, Inc. - Englewood CO

A61K 922, A61K 926

424 19

A constant order release rate solid oral dosage formulation of hydralazine or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of hydralazine or a pharmaceutically acceptable salt; from about 0. 5 to 6. 0 weight percent of an acid-retardant or hydrophobic cellulose derivative; from about 2. 5 to 35 weight percent of a hydrogenated vegetable oil: from about 1 to 20 weight percent of an acrylic acid polymer; from about 0. 5 to 4. 0 weight percent of fumed silicon dioxide and from about 0. 4 to 3. 0 percent of a lubricant.

4522804, Jun 11, 1985

Feb 16, 1984

6/580823

James M. Dunn - Littleton CO

Verex Laboratories, Inc. - Englewood CO

A61K 922, A61K 926

424 19

A constant order release rate solid oral dosage formulation of propranolol or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of propranolol or a pharmaceutically acceptable salt; from about 0. 5 to 6. 0 weight percent of an acid-retardant or hydrophobic cellulose derivative; from about 2. 5 to 35 weight percent of a hydrogenated vegetable oil: from about 1 to 20 weight percent of an acrylic acid polymer; from about 0. 5 to 4. 0 weight percent of fumed silicon dioxide and from about 0. 4 to 3. 0 percent of a lubricant.

2006022, Oct 12, 2006

Mar 17, 2006

11/384196

Dallas Clouatre - Santa Monica CA, US
James Dunn - Littleton CO, US
Caroline Dunn - Littleton CO, US

A61K 31/366, A61K 31/19, A61K 9/46

424466000, 514574000, 514460000

The inventors have discovered that food and pharmaceutical compositions containing (−)-hydroxycitric acid, its salts, amides and esters can be employed for delaying gastric emptying and increasing receptive relaxation for preventing and treating diverse conditions. The invention provides for HCA-containing compound useful to delay gastric emptying and increase receptive relaxation for preventing and treating diverse conditions, e.g., stomach ulcers, portal hypertension, liver dysfunction, diabetes and obesity. The invention provides methods for delaying gastric emptying and increasing receptive relaxation in individuals. The invention also provides methods of preventing or treating disorders or conditions related to aberrant gastric emptying and receptive relaxation.

4525345, Jun 25, 1985

Aug 6, 1984

6/637843

James M. Dunn - Littleton CO
Ronald T. Haas - Highland Ranch CO

Verex Laboratories, Inc. - Englewood CO

A61K 922, A61K 930, A61K 952, A61K 956

424 22

A constant release rate indomethacin formulation in tablet unit dosage form, said tablet comprising an intimate admixture of from 50 to 200 mg of indomethacin, from about 1. 7 to 3. 7 weight percent of a slow-dissolving, water-insoluble cellulose derivative, from about 1. 5 to 5. 0 weight percent of a tabletting disintegrant, and from about 40 to 80 weight percent of a pharmaceutically acceptable bulking agent or diluent.